Telix Pharmaceuticals names David Gill as Board Chair
Gill succeeds Dr. Mark Nelson, who had served as interim Chair and will stay on the board as a Non-Executive Director.
SEC filing
Latest
3 stories
Monday, August 31
Wednesday, August 5
Evolus raises 2026 revenue guidance, adds Profhilo to U.S. pipeline via IBSA deal
The aesthetics company posted 21% revenue growth for the second quarter, expanded its injectable portfolio with new licensing deals, and reaffirmed 2028 targets.
SEC filing
Tuesday, August 4
Evolus expands Symatese pact to add Canada, Australia, New Zealand for Estyme
The amendment gives Evolus exclusive rights to sell the HA gel line in three more markets, with commercialization targeted for 2028.
SEC filing